AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
NCT07400107 on ClinicalTrials.gov · last registry update 2026-03-12
An unusually large phase 3: 1,000 participants, more than double the 424 typical for the stage. Due to report 12 December 2028, alongside 16 other tracked readouts that quarter. Primary outcome, as filed: Relative change in body weight. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for obesity and type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- NOT_YET_RECRUITING
- Phase
- P3
- Drug
- semaglutideRybelsus, Wegovy, Ozempic
- Sponsor
- Novo Nordisk A/S
- Sponsor type
- Industry
- Enrollment
- 1,000
- Started
- 2026-05-20
- Primary completion
- 2028-12-12 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Relative change in body weight
Conditions studied
Obesity · Overweight · Diabetes Mellitus, Type 2
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.